Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
ADAR1 Capital Management LLC and related entities reported significant trading activity in Keros Therapeutics (KROS) securities on June 20, 2025. The transactions involved both direct stock sales and put option exercises:
- ADAR1 Partners LP disposed of 1,500 shares of common stock: - 100 shares at $60 per share - 1,400 shares at $70 per share
- Spearhead Insurance Solutions IDF LLC disposed of 200 shares at $70 per share
- Related put options were exercised, corresponding to the stock dispositions: - One $60 strike put option for 100 shares - Sixteen $70 strike put options for 1,600 shares total
Following these transactions, ADAR1 Partners LP maintains beneficial ownership of 4,391,237 shares, while Spearhead Insurance Solutions holds 743,358 shares. All reporting persons are considered 10% owners of Keros Therapeutics, with Daniel Schneeberger serving as the manager of the related entities.